|
|
|
| Expression and Clinical Significance of MMP-2, MMP-9 and CEACAM-1 in Colon Cancer |
| WANG Gong-li, HUANG Yong-nian |
| Department of General Surgery, Shanyang County People's Hospital, Shanyang 726400 |
|
|
|
|
Abstract 【Objective】To investigate the expression levels of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and carcinoembryonic antigen-associated cell adhesion molecule-1 (CEACAM-1) in colon cancer tissues and the correlation with clinicopathological factors and prognosis. 【Methods】Sixty colon cancer patients who underwent radical resection of colon cancer in our hospital were enrolled. The samples of cancer tissues, paracancerous tissues and normal colon tissues were obtained and the expression levels of MMP-9, MMP-2 and CEACAM-1 were detected. The correlation of clinicopathological factors and disease-free survival (DFS) with expression of MMP-9, MMP-2 and CEACAM-1 were analyzed. 【Results】The positive rates of MMP-9, MMP-2 and CEACAM-1 expression in cancer tissues were higher than those in adjacent tissues and normal colon tissues(P<0.05), and the positive rates of MMP-9, MMP-2 and CEACAM-1 expression in adjacent tissues were higher than normal colon tissue (P<0.05). The expressions of MMP-9, MMP-2 and CEACAM-1 were correlated with serosal invasion, TNM staging, lymph node metastasis and vascular invasion (P<0.05), and their expressions were not correlated with tumor diameter and tumor differentiation (P>0.05). The patients were followed up for 12-38 months, and 28 patients with recurrence and metastasis were showed up. COX multivariate analysis showed that MMP-9, MMP-2, CEACAM-1, TNM, lymph node metastasis were independent prognostic factors for DFS. 【Conclusion】MMP-9, MMP-2 and CEACAM-1 are highly expressed in colon cancer tissues, and high expression is associated with poor prognosis.
|
|
Received: 29 September 2020
|
|
|
|
|
|
[1] QI L, DING Y. Screening of differentiation-specific molecular biomarkers forcolon cancer[J].Cell Physiol Biochem,2018,46(6):2543-2550.
[2] 陶晓峰,张明,杨东, 等.CEACAM-1和MMP-2在结直肠癌中的表达及与淋巴结转移的关系[J].山西医科大学学报,2018,49(11):1346-1350.
[3] WIECZOREK E, JABLONOWSKI Z, TOMASIK B, et al. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer[J].Clin Biochem,2015,48(18):1235-1240.
[4] LIU C, LI Y, HU S, et al. Clinical significance of matrix metalloproteinase-2 in endometrial cancer: A systematic review and meta-analysis[J].Medicine (Baltimore),2018,97(29):e10994.
[5] LORENC Z, WANICZEK D, LORENC-PODGORSKA K, et al. Profile of expression of genes encoding MMP9, MMP28 and TIMP1 in colorectal cancer: Assessment of the role in diagnosis and prognostication[J].Med Sci Monit,2017,23:1305-1311.
[6] XU B, LI K P, SHEN F, et al. Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway[J].Biomed Res Int,2013,2013(9):437-450.
[7] YANG B, TANG F, ZHANG B, et al. Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer[J].World J Surg Oncol,2014,12(1):24.
[8] KRYCZKA J, STASIAK M, DZIKI L, et al. Matrix metalloproteinase-2 cleavage of the beta1 integrin ectodomain facilitates colon cancer cell motility[J].J Biol Chem,2012,287(43):36556-36566.
[9] LIN S, JIANG T, YU Y, et al. Secernin-1 contributes to colon cancer progression through enhancing matrix metalloproteinase-2/9 exocytosis[J].Dis Markers,2015,23(7),503-505.
[10] HAN Z M, HUANG H M, SUN Y W. Effect of CEACAM-1 knockdown in human colorectal cancer cells[J].Oncol Lett,2018,16(2):1622-1626. |
|
|
|
2022, Vol. 39 
